HARMONY



ALLIANCE



Let's connect at ASH2022

Attend to the HARMONY Alliance abstract presentations and view the posters.

Join the HARMONY Alliance – ELN Network Breakfast Meeting. Meet us at the EHA booth nr. 2822 at the ASH2022 exhibition.

↓*EHA

Participate in the joint ASH RC – HARMONY Alliance session: Driving Real-World Evidence for Hematologic Malignancy Research.

The HARMONY Alliance is the European Public-Private Partnership for Big Data in Hematology.

64th Annual Meeting of the American Society of Hematology


ASH2022 | 10-13 December 2022 Ernest N. Morial Convention Center in, New Orleans, Louisiana, USA

#BigDataforbloodcancer

Accelerating better and faster treatment for Blood Cancer Patients

The HARMONY Alliance is a unique European partnership of more than 100 public and private organizations, funded by the Innovative Health Initiative. HARMONY is using big data analytics to mine the 73,000 records already available on the HARMONY Big Data Platform and addresses pressing research questions for patients with Hematologic Malignancies. Ultimately, our research teams aim to accelerate the development of personalized treatments.

Did we trigger your interest? Let's connect! We look forward to presenting our big data research projects, explaining the HARMONY data journey and how data quality, safety, and privacy are ensured. Co-operative working groups, hospitals and academic institutions are invited to collaborate and contribute data to the HARMONY Alliance.



- Custom-built Big Data Platform
- Unique anonymization concept
- State of the art Big Data analytic services



Projects:

- Big Data Research
- Delphi Surveys for Core Outcome Sets
- Multi-stakeholder activities
- Communications

HARMONY Alliance activities at ASH2022

For your calendar - timeline in CST:

SATURDAY - DECEMBER 10, 2022				
03:00 PM	Oral	Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications		
04:45 PM	Oral	Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML		
05:30 - 07:30 PM	Poster	Pan-Stakeholder Core Outcome Set (COS) definition for Hematological Malignancies		

SUNDAY - DECEMBER 11, 2022				
06:00 - 10:00 AM	Session	ELN — European Leukemia Network Breakfast Meeting		
06:00 - 08:00 PM	Poster	Long-term follow-up of AML patients treated intensively before the era of targeted agents. A big data analysis		
06:00 - 08:00 PM	Poster	Robust validation of the UKALL high hyperdiploid risk profile using individual patient data		
06:00 - 08:00 PM	Poster	IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk- Adapted Pethema LAL19 Trial		

MONDAY - DECEMBER 12, 2022

04:30 - 06:00 PM	Session	Joint ASH RC – EU HARMONY Alliance session:
		Driving Real-World Evidence for Hematologic
		Malignancy Research

Find our documentation in the booth (**2822**) of the European Hematology Association, EHA.

Opening hours ASH2022 exhibition:

10 Dec. 11:00 AM - 05:00 PM 11 Dec. 10:00 AM - 05:00 PM 12 Dec. 10:00 AM - 02:00 PM

ABSTRACTS

HARMONY Alliance research results and presentations

SATURDAY - DECEMBER 10, 2022



Oral: Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database Alberto Hernández, University Hospital of Salamanca

- Session Name: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Lesions and Therapeutic Implications
- Session Time: 02:00 PM 03:30 PM
- Presentation Time: 03:00 PM
- Room: Ernest N. Morial Convention Center, 291-292
- Publication Number: 227
- Submission ID: 167480
- https://ash.confex.com/ash/2022/webprogram/Paper167480.html





Oral: Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance Alberto Hernández, University Hospital of Salamanca

- Session Name: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Molecular Features and Response to Treatment in AML
- Session Time: 04:00 PM 05:30 PM
- Presentation Time: 04:45 PM
- Room: Ernest N. Morial Convention Center, 388-390
- Publication Number: 304
- Submission ID: 167138
- https://ash.confex.com/ash/2022/webprogram/Paper167138.html



SATURDAY - DECEMBER 10, 2022



Poster: Pan-Stakeholder Core Outcome Set (COS) definition for Hematological Malignancies within the framework of HARMONY and HARMONY PLUS projects Katharina Lang, Charité Universitätsmedizin Berlin, Germany

- Session Name: 906. Outcomes Research-Myeloid Malignancies: Poster I
- Presentation Time: 05:30 PM 07:30 PM
- Location: Ernest N. Morial Convention Center, Hall D
- Publication Number: 2316
- Submission ID: 157549
- https://ash.confex.com/ash/2022/webprogram/Paper157549.html

SUNDAY - DECEMBER 11, 2022





Poster: Long-term follow-up of AML patients treated intensively before the era of targeted agents - A big data analysis from the HARMONY collaboration Marta Sobas, Medical University of Wroclaw

- Session Name: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
- Presentation Time: 06:00 PM 08:00 PM
- Location: Ernest N. Morial Convention Center, Hall D
- Publication Number: 2697
- Submission ID: 165088
- https://ash.confex.com/ash/2022/webprogram/Paper165088.html





Poster: Robust validation of the UKALL high hyperdiploid risk profile using individual patient data collected by the HARMONY alliance Anthony Moorman, University of Newcastle

- Session Name: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
- Presentation Time: 06:00 PM 08:00 PM
- Location: Ernest N. Morial Convention Center, Hall D
- Publication Number: 2834
- Submission ID: 157680
- https://ash.confex.com/ash/2022/webprogram/Paper157680.html






Poster: IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial Jordi Ribera, IJC Josep Carreras Leukaemia Research Institute

- Session Name: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
- Presentation Time: 06:00 PM 08:00 PM
- Location: Ernest N. Morial Convention Center, Hall D
- Number: 2822
- https://ash.confex.com/ash/2022/webprogram/Paper162159.html




The HARMONY Alliance uses big data technologies to improve the treatment of blood cancers

Data are stored in the HARMONY Big Data Platform, which has already identified over 150,000 anonymized patient records, making it one of the largest databases of its kind. Leading research teams are currently using this wealth of information to answer critical questions about hematologic malignancies that cannot be addressed with other methods.



The HARMONY Big Data Platform offers a central database and state-of-the-art Big Data analytic services. The anonymous data at the Big Data Platform, donated by our Partners and Associated Members, is collected securely following all legal and ethical requirements, harmonized and then analyzed. Here emerge various data sets from different data providers – pharma, biobanks, hospitals, interventional, and non-interventional trials.

The HARMONY Big Data Platform









HARMONY Alliance - ELN Breakfast Meeting

SUNDAY - DECEMBER 11, 2022

07:30-10:00 AM | Astor Crown Plaza, Level 2, 739 Canal Street @ Bourbon Street, New Orleans | Room Astor Gallery by Astor Ballroom II and III

During this 90 minutes session summary reports will be presented by ELN Work Package Leaders in CML, AML-MRD, R/R AML, ALL, CLL, MDS, MPN, SCT. The leadership of the HARMONY Alliance will present updates of HARMONY and HARMONY PLUS, as well as our plans for the future. Email to; communications@harmony-alliance.eu to receive our detailed session program.

SESSION





Joint ASH RC – EU HARMONY Alliance session:

Driving Real-World Evidence for Hematologic Malignancy Research

MONDAY - DECEMBER 12, 2022

04:30 - 06:00 PM | Room 217-219 | New Orleans Morial Convention Centers

This 90-minute session will address how the ASH Research Collaborative's Data Hub Program and the European HARMONY Alliance program are exploring opportunities to capture real-world data to generate real-world evidence that supports research and collaborative clinical practice in Hematologic Malignancies.

Speakers in the joint ASH RC – HARMONY Alliance session will elaborate on the role of real-world data collection in Hematologic Malignancies across the ASH RC Data Hub and the HARMONY Alliance. Like the ASH RC Data Hub Program, the HARMONY Big Data Platform is a step toward breaking down these data silos and exploiting the potential of Big Data to improve the treatments and quality of care for patients with hematologic malignancies.

Read more about:

- → The ASH Research Collaborative: www.ashresearchcollaborative.org
- → The ASH RC Data hub: www.ashresearchcollaborative.org/s/data-hub
- → The HARMONY Alliance: www.harmony-alliance.eu
- → The HARMONY Big Data Platform: www.harmony-alliance.eu/bigdata-platform
- → HARMONY Research Projects: www.harmony-alliance.eu/projects

Impact of Real-World Evidence on research and clinical care: Priorities from the ASH RC Data Hub and from the HARMONY Alliance



Adam Sperling, Dana-Farber Cancer Institute, USA - ASH RC



Jesús Maria Hernández Rivas, MD, PhD, IBSAL, Spain HARMONY Alliance

Pandemic Preparedness: Highlighting the role of Real-World Data hub programs A Regulators View: The impact of reliable and relevant Real-World Data on measuring safety and efficacy



William A. Wood, UNC Healthcare, USA ASH RC



Kanapuru Bindu, U.S. Food and Drug Administration FDA

HARMONY Alliance: Moving toward multicenter Real-World Data capture in the Hematologic Malignancies in Europe



Konstanze Döhner, Ulm University, Germany HARMONY Alliance



Jan Geissler, Leukanet HARMONY Alliance

Building Real-World research and collaborative practice networks for Malignant Hematology



Donna Neuberg, Dana-Farber Cancer Institute, USA - ASH RC



Brian Huntly, University of Cambridge, UK HARMONY Alliance

Call to action for clinicians, researchers, regulators about data sharing, harmonization, and analytic considerations



Lars Bullinger, Charité – Germany HARMONY Alliance

Join the largest European Public-Private Partnership for Big Data in Hematology

Co-operative working groups, hospitals and academic institutions are invited to collaborate and contribute data to the HARMONY Alliance.

The HARMONY Alliance is a public-private European Network of Excellence for Big Data in Hematology. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies.

What can we offer you?

- Submit research proposals.
- Become a member of a dedicated research group that includes skilled data scientists
- Contribute to scientific publications under the umbrella of the HARMONY Alliance
- Be compensated for your efforts in sharing your data
- Contribute to improving outcomes for individuals with blood cancer.

How can you join?

Follow the steps below to join the HARMONY Alliance and become an Associated Member:



STEP 1

Email us: communications@harmony-alliance.eu to express your interest.



STEP 2

Use a Data Dictionary to describe the data you wish to contribute to the HARMONY Big Data Platform. HARMONY will then estimate compensation for your invested efforts.



STEP 3

Your institution's legal representative signs the 'Associated Members Data Sharing' agreement.



STEP 4

Welcome to the HARMONY Community. Start sharing your data!

The HARMONY Alliance represents over 100 organizations and consists of two projects: HARMONY and HARMONY PLUS. Funding is received from the Innovative Medicines Initiative (as of 2022 called IHI, Innovative Health Initiative), supported by the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).



Join us in creating the next generation of care for blood cancer patients

G Data-driven science will help to meet the needs of **blood cancer patients** by increasing treatment efficacy, decreasing adverse effects, prolonging survival, and contribute to patients' **quality of life**."

The HARMONY Allance is a public-private Luropean Network of Excellence for big Data In Hematology, Dur mission is to funck and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies. The HARMONY Allance consists of two projects funded through the Innovative Medicines Initiative las of 2022 called HI, Innovative Health Initiative, IAARMONY Pulls, Funding Is received from the IMI 2 Joint Undertaking and Is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PULS No. 954-960. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

У in f 🖸 www.harmony-alliance.eu



